Ask about this productRelated genes to: TACC3 antibody
- Gene:
- TACC3 NIH gene
- Name:
- transforming acidic coiled-coil containing protein 3
- Previous symbol:
- -
- Synonyms:
- ERIC1
- Chromosome:
- 4p16.3
- Locus Type:
- gene with protein product
- Date approved:
- 1998-10-12
- Date modifiied:
- 2019-04-23
Related products to: TACC3 antibody
Related articles to: TACC3 antibody
- The immunosuppressive tumor microenvironment (TME) limits immunotherapy efficacy in intrahepatic cholangiocarcinoma (ICC). Understanding the molecular drivers of this TME is essential for developing new therapies. This study aimed to identify novel oncogenes that modulate the immune landscape of ICC using a multi-omics approach. - Source: PubMed
Publication date: 2026/04/10
Wang HaoXu ZhiquanZhang ZiqiYou YanXu RanningChen HongliCui HongshuaiLuo XiaoyongLiao Rui - MET exon 14 skipping mutation (METΔex14) is a key driver event in non-small cell lung cancer (NSCLC) and can emerge as an acquired drug resistance mechanism to MET, EGFR or ALK inhibitors. The clinical and genomic features of METΔex14 in NSCLC require further characterization. - Source: PubMed
Publication date: 2026/05/23
Lin JieXia GuojieWu YijuanChen LingfengZhang YaruMa YaYin Jiani CZhang ZhenyuPan Xiaojie - Aneuploidy is a hallmark of cancer and is a potential vulnerability that can be selectively targeted. To systematically identify genes that affect the incidence and fitness of aneuploid cells, we conducted a genome-wide CRISPR/Cas9 screen using NMS-P715, an inhibitor of the spindle assembly checkpoint (SAC) kinase MPS1/TTK. In this study, we identified several genes known to regulate aneuploidy and mitosis, and subsequently focused on , a ubiquitously expressed gene previously implicated in chronic myelomonocytic leukemia (CMML). Proximity labeling of PRR14L using TurboID revealed several cell division proteins, including the PP2A-B56 phosphatase complex and the spindle assembly factor TACC3, as PRR14L-interacting proteins. Loss of PRR14L prolongs SAC-dependent mitotic arrest in response to microtubule depolymerization but, paradoxically, leads to catastrophic mitotic errors upon SAC abrogation by MPS1 inhibitors. A model derived from our findings provides a rationale for exploiting MPS1 inhibition as a potential vulnerability in cancers containing either PRR14L loss of function mutations or FGFR-TACC3 fusions. - Source: PubMed
Publication date: 2026/05/20
Liu Albert ZNarkar AkshayLi KemingBertomeu ThierryJohnson Blake ACoulombe-Huntington JasminDong YiZhu JinTyers MikeLi Rong - The latest bladder cancer (BC) urine tests based on multiple genomic and/or epigenomic markers detect BC with high sensitivity and specificity. The GALEAS Bladder (GB) gene panel covers several actionable mutations, including in FGFR3. - Source: PubMed
Publication date: 2026/05/05
Neil Jessica LGordon Naheema SGoel AnshitaMyumyun Ayse NTura Benjaminde Jong Joep JDavicioni ElaiZeegers Maurice PCheng Kar KeungJames Nicholas DNeou MarioArnold RolandBryan Richard TWard Douglas G - Comprehensive genomic profiling test (CGPT) using next-generation sequencing (NGS) plays a vital role in cancer diagnosis, treatment option, and prognostic evaluation. In Japan, three tissue-based CGPTs, FoundationOne® CDx, GenMineTOP, and NCC OncoGuide™, are reimbursed under public health insurance. However, their comparative performance in central nervous system (CNS) tumors remains unclear. - Source: PubMed
Publication date: 2026/05/06
Kawauchi DaisukeOhno MakotoTakahashi MasamichiKoyama TakafumiSunami KunikoHirata MakotoYanagisawa ShunsukeOmura TakakiAoki TakumaFujii GentaSaito KojiYamamoto TetsuyaSuzuki HiromichiNarita Yoshitaka